Testosterone replacement therapy gets discussed online as either a miracle fix or a dangerous shortcut, with a lot of confident claims on both sides. The best available evidence — a large, purpose-built clinical trial — gives a much more precise, nuanced picture than either extreme.
The Study That Actually Answers the Safety Question
For years, the biggest question hanging over TRT was cardiovascular safety — did it increase heart attack and stroke risk? That question was directly answered by the TRAVERSE trial, led by Dr. Steven Nissen and Dr. A. Michael Lincoff, published in the New England Journal of Medicine in 2023. This was a large, randomized, placebo-controlled trial specifically designed to test cardiovascular safety in middle-aged and older men with confirmed hypogonadism (clinically diagnosed low testosterone, generally under 300 ng/dL) who also had existing or high cardiovascular risk.
What It Found: The Headline Result
Testosterone therapy was not associated with an increased risk of major cardiovascular events. The primary combined endpoint (cardiovascular death, non-fatal heart attack, or non-fatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group — essentially no meaningful difference. This was a genuinely important finding, since cardiovascular risk had been the main safety concern preventing wider, more confident use of TRT in men who need it.
What It Also Found: Real Risks That Did Show Up
The trial wasn't a blanket "all clear" — three specific adverse events occurred at meaningfully higher rates in the testosterone group:
- Atrial fibrillation (an irregular heart rhythm): 3.5% vs. 2.4% in the placebo group
- Acute kidney injury: 2.3% vs. 1.5%
- Pulmonary embolism (a blood clot in the lungs): 0.9% vs. 0.5%
These are real, measurable increased risks, even though the primary cardiovascular safety endpoint didn't show harm. This is exactly why TRT is a medical decision, made with a doctor monitoring bloodwork and symptoms — not a supplement to self-administer.
The Critical Limitation Everyone Should Know
The researchers were explicit about scope: these findings apply specifically to men with diagnosed, confirmed hypogonadism who meet clear clinical criteria — not to otherwise healthy men chasing performance or aesthetic benefits without an actual medical diagnosis. Using testosterone therapy without genuinely low levels and a medical indication is a different risk calculation entirely, and this study doesn't provide safety reassurance for that use case.
What This Means If You're Considering TRT
- Get actual bloodwork. "I feel tired and unmotivated" is not the same as a confirmed low testosterone diagnosis — get tested properly before considering treatment.
- TRT is legitimately safer, on the cardiovascular front, than previously feared — for men who actually have diagnosed hypogonadism and are monitored by a physician.
- It's not risk-free. Elevated risks of atrial fibrillation, kidney injury, and blood clots are real considerations to discuss with your doctor, not reasons to self-medicate around.
- This is not a green light for off-label or unsupervised use. The safety data here doesn't extend to men using testosterone without a genuine medical need, often at doses and monitoring standards nothing like a clinical trial.
The Takeaway
The best current evidence shows TRT, for men with properly diagnosed low testosterone, doesn't raise cardiovascular risk the way many feared — but it does come with real, measurable risks around heart rhythm, kidney function, and blood clotting that deserve genuine medical oversight. It's neither the miracle nor the menace it's often portrayed as online — it's a legitimate medical treatment, for a specific diagnosis, with a real risk-benefit profile that a doctor needs to manage.
References
- Lincoff, A. M., Bhasin, S., Flevaris, P., et al. (2023). Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine, 389, 107-117. (The TRAVERSE Trial)
Discussion